SEC Comment Letter 0000000000-22-013274 to Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc.
Date: Dec. 9, 2022 · CIK: 0001645460 · Accession: 0000000000-22-013274
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268687
Letter
United States securities and exchange commission logo December 9, 2022 Kerri-Ann Millar Chief Financial Officer Cue Biopharma, Inc. 40 Guest Street Boston, MA 02135 Re:Cue Biopharma, Inc. Registration Statement on Form S-3 Filed December 6, 2022 File No. 333-268687 Dear Kerri-Ann Millar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cynthia Mazareas, Esq.
Show Raw Text
United States securities and exchange commission logo
December 9, 2022
Kerri-Ann Millar
Chief Financial Officer
Cue Biopharma, Inc.
40 Guest Street
Boston, MA 02135
Re:Cue Biopharma, Inc.
Registration Statement on Form S-3
Filed December 6, 2022
File No. 333-268687
Dear Kerri-Ann Millar:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Cynthia Mazareas, Esq.